The share prices of blue-chip biopharmaceutical companies closed out the month on a high note to contribute to their stellar collective performance during the second quarter, with the BioWorld Biopharmaceutical index increasing almost 20%.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alterity, Ardelyx, Astrazeneca, Bioinvent, Mediwound, Merck, Nuvox, Oncopeptides, Oncternal, Osmotica, Prestige, Sparingvision, Synthetic Biologics, Vericel, Verrica.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advanced Accelerator, Audentes, Basilea, Bioasis, Blueprint, Burning Rock, Camino, CNS, Cstone, Genespire, Hoth, Immatics, Marker, Meissa, Novartis, Optinose, Vertex, Ziphius.
Hong Kong – China’s Kangji Medical Holdings Ltd. has made a memorable debut on the Hong Kong Stock Exchange (HKEX), with shares jumping 98.84% from their opening price of HK$13.88 (US$1.79) to close at HK$27.60 (US$3.56) on the first day of trading on June 29.
Gilead Sciences Inc. ended the speculation Monday when it announced its no-bargaining price for remdesivir for all governments of developed countries where the drug is approved or authorized as a treatment for COVID-19.
Multiple sessions at the American Association for Cancer Research Virtual Annual Meeting II covered how COVID-19 is affecting cancer patients, from how clinical trials needed to be modified during the pandemic to how real-world evidence can play a role now and in the future.
RSS
